Development of selective tolerance to the serotonin behavioral syndrome and suppression of locomotor activity after repeated administration of either 5-MeODMT or mCPP.
Life Sciences July 1, 1985 DOI: 10.1016/0024-3205(85)90142-0 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Experimental study Peer reviewed |
|---|---|
| Population | Rats |
| Interventions | 5-MeODMT mCPP |
| Topics | Serotonin |
| Citations | 54 |
| Key findings | Repeated administration of 5-HT1A or 5-HT1B agonists produces tolerance specific to the receptor subtype, indicating that the serotonin behavioral syndrome and suppression of locomotor activity are mediated by different 5-HT1 receptor subtypes. |
Abstract
Repeated administration to rats of the 5-HT1A-selective agonist 5-methoxy-N,N-dimethyltryptamine (5-MeODMT) produced tolerance to the ability of a test dose of 5-MeODMT to produce the serotonin behavioral syndrome, but not to the ability of a test dose of the 5-HT1B-selective agonist m-chlorophenylpiperazine (mCPP) to decrease locomotor activity. Conversely, repeated administration of mCPP produced tolerance to the ability of a test dose of mCPP to decrease locomotor activity, but not to the ability of a test dose of 5-MeODMT to elicit the serotonin behavioral syndrome. The lack of cross-tolerance between these two selective agonists is consistent with the idea that the serotonin behavioral syndrome and suppression of locomotor activity are mediated by different subtypes of the 5-HT1 receptor.